HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Reinvestment Rate
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Reinvestment Rate of 2.46x as of September 2025, reinvesting ₩4.60 Billion (capex ₩2.26 Billion plus investments ₩2.34 Billion) from operating cash flow of ₩1.86 Billion. Explore HLB Pharmaceutical Co. Ltd (047920) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
HLB Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for HLB Pharmaceutical Co. Ltd across 3 annual periods. Also explore 047920 total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for HLB Pharmaceutical Co. Ltd. For live market cap and broader valuation context, see 047920 market cap.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.24x | ₩15.35 Billion | ₩6.84 Billion | ₩3.09 Billion | ▼ -53.0% |
| 2019 | 4.77x | ₩6.46 Billion | ₩1.35 Billion | ₩1.40 Billion | ▲ +95.2% |
| 2014 | 2.44x | ₩3.77 Billion | ₩1.54 Billion | ₩2.26 Billion | — |